Aktuellt
SENASTE
Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 targeting Parkinson’s disease. Herantis reiterates its guidance to initiate the study in H1 2023, pending approval. We will return with a research update in early January to discuss the study in-depth.
LÄS MER
